Clinical trials: Indonesia
Malaria
Safety, Tolerability, Immunogenicity and Protective Efficacy of PfSPZ Vaccine and PfSPZ-CVac in Indonesian Adults Against Naturally-Transmitted Malaria
The study is a double-blind, randomized, placebo-controlled, Phase 2 clinical trial that will assess the safety, tolerability, immunogenicity and protective efficacy of PfSPZ Vaccine and PfSPZ-CVac against naturally occurring…
- Trial name
- NCT03503058
- Testing
- PfSPZ Vaccine, PfSPZ Challenge under chloroquine (CQ) chemoprophylaxis, Normal Saline
- Where
- 2 sites in Indonesia
- Volunteers
- 345 people, healthy volunteers welcome
- Sponsor
- Sanaria Inc.
COVID-19
A Study to Understand is the COVID-19 Vaccine BNT162b2 is Safe in Indonesia People
The purpose of this study is to characterize descriptively the BNT162b2 vaccination safety experience among the Indonesian people.
- Trial name
- NCT05621239
- Testing
- BNT162b2
- Where
- Indonesia
- Volunteers
- 260 people
- Sponsor
- Pfizer
Infectious Disease
Observational Research on Infectious Disease Outbreaks and Difficult Cases of Unidentified Etiology in Indonesia
This observational study will investigate suspected infectious diseases of unknown etiology prospectively during outbreaks and at healthcare facilities, and retrospectively through historical samples where no etiology was ever…
- Trial name
- INA-ORCHID (NCT04339179)
- Where
- 19 sites in Indonesia
- Volunteers
- 185 people
- Sponsor
- Ina-Respond
COVID-19
Evaluation of Full Versus Fractional Doses of COVID-19 Vaccines Given as a Booster in Adults in Australia - Mongolia, Indonesia, Australia Coronavirus (MIACoV).
This is a single-blind, randomised controlled clinical trial to determine the reactogenicity and immunogenicity of severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) vaccines (Pfizer-BioNTech or Moderna) as booster dose…
- Trial name
- MIACoV (NCT05228730)
- Testing
- Tozinameran - Standard dose, Tozinameran - fractional dose, Elasomeran - standard dose
- Where
- Australia
- Volunteers
- 13 people, healthy volunteers welcome
- Sponsor
- Murdoch Childrens Research Institute
Precapillary Pulmonary Hypertension
The Role of Trimetazidine on Right Ventricle Function in Pulmonary Arterial Hypertension
The study will evaluate the effect of trimetazidine versus placebo in addition to standard pulmonary arterial hypertension regime on right ventricular function in pulmonary arterial hypertension patients.
- Trial name
- TRIMETA-PH (NCT03273387)
- Testing
- Trimetazidine
- Where
- Indonesia
- Volunteers
- 26 people
- Sponsor
- Universitas Indonesia
Idiopathic Parkinson's Disease, Drug Induced Dyskinesia
Topiramate as an Adjunct to Amantadine in the Treatment of Dyskinesia in Parkinson's Disease
The study will involve an eighteen-week, double-blind, placebo-controlled parallel designed comparison between add-on topiramate and add-on placebo to stable treatment with amatadine in the treatment of Parkinson's disease (PD)…
- Trial name
- TOP-DYSK (NCT01789047)
- Testing
- Topiramate, Amantadine
- Where
- 5 sites in United States
- Volunteers
- 42 people
- Sponsor
- Rush University Medical Center
Healthy
Glucophage® Extended Release (XR) 750 Milligram (mg) Indonesia Bioequivalence (BE) Study
The purpose of this study is to assess bioequivalence between metformin hydrochloride (Glucophage® XR) manufactured in PT Merck Tbk, Indonesia (test drug) and metformin hydrochloride (Glucophage® XR) manufactured in Merck Santé…
- Trial name
- NCT03583385
- Testing
- Glucophage XR (Test drug), Glucophage XR (Comparator drug)
- Where
- Indonesia
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Merck KGaA, Darmstadt, Germany
Acute Febrile Illness
The Etiology of Acute Febrile Illness Requiring Hospitalization
This study is an observational cohort study of hospitalized patients with fever. This study will collect demographic data, history of illness, signs and symptoms, results of laboratory tests, clinical course, treatment and…
- Trial name
- AFIRE (NCT02763462)
- Where
- 8 sites in Indonesia
- Volunteers
- 1,492 people
- Sponsor
- Ina-Respond
Drug Use
Pharmacokinetic Properties of 200 and 400 mg Acyclovir Tablet in Indonesia Healthy Subject
The objective of this present study was to asses the pharmacokinetic properties of acyclovir tablet from new product formulation (PT.
- Trial name
- NCT04988646
- Testing
- Acyclovir 200 MG, Acyclovir 400 MG, Zovirax 200 MG Tablet
- Where
- Indonesia
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- PT. Kimia Farma (Persero) Tbk
Influenza
A Trial to Test the Response to Different Vaccination Regimens With an H5N1 Vaccine With AS03 in Adults Aged 18-64
The purpose of the study is to characterize the immunogenicity \& safety of 2 doses of GSK's avian flu vaccine GSK 1557484A given according to different regimens to adults aged 18 to 64 years
- Trial name
- NCT00695669
- Testing
- Influenza A (H5N1) Virus Monovalent Vaccine
- Where
- 3 sites in Canada
- Volunteers
- 312 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Influenza
Safety and Immunogenicity of PanBlok Influenza Vaccine in Healthy Adults
The purpose of this study is to investigate the safety and immunogenicity of a recombinant hemagglutinin (rHA) influenza vaccine derived from A/Indonesia/05/2005 (H5N1) administered at 4 dose levels in adjuvanted (GLA-SE) rHA…
- Trial name
- NCT01147068
- Testing
- 0.5mL Intramuscular Injection
- Where
- 4 sites in United States
- Volunteers
- 392 people, healthy volunteers welcome
- Sponsor
- Protein Sciences Corporation
Pulmonary Tuberculosis, Body Weight Changes
Fermented Soybean Supplementation Among Active Pulmonary Tuberculosis Patients With Standard Therapy in Indonesia
Tuberculosis (TB) patients often have a lower body mass index (BMI) and experience wasting. Wasting reduces lean body mass and may cause physical function impairment.
- Conditions
- Pulmonary Tuberculosis, Body Weight Changes, Motor Activity
- Trial name
- FSS (NCT02554318)
- Testing
- Rifampicin, Isoniazid, Pyrazinamide
- Volunteers
- 147 people
- Sponsor
- University of Giessen
Pneumonia
Implementing a Combination of Clinical Parameters, Biomarkers and SoCs for the Etiology Diagnoses of Pneumonia in Pediatric Patients
Participants who meet the inclusion and exclusion criteria will be enrolled and then having a daily follow up for maximum of 13 days' hospitalization.
- Trial name
- PEER-PePPes (NCT03366454)
- Where
- 4 sites in Indonesia
- Volunteers
- 188 people
- Sponsor
- INA-RESPOND Secretariat